RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $31.
September 05, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for NewAmsterdam Pharma, maintaining a price target of $31. This suggests confidence in the company's future performance.
The reiteration of an Outperform rating and a maintained price target of $31 by RBC Capital indicates a positive outlook for NewAmsterdam Pharma. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100